ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

September 1, 2025

Conditions
Purpura, Thrombocytopenic
Interventions
DRUG

Aspirin

Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2

Trial Locations (1)

Unknown

RECRUITING

Toulouse Hospital, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER